BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8305741)

  • 1. Tiazofurin decreases Ras-GTP complex in K562 cells.
    Hata Y; Natsumeda Y; Weber G
    Oncol Res; 1993; 5(4-5):161-4. PubMed ID: 8305741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
    Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
    Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells.
    Olah E; Kote Z; Natsumeda Y; Yamaji Y; Jarai G; Lapis E; Financsek I; Weber G
    Cancer Biochem Biophys; 1990 Apr; 11(2):107-17. PubMed ID: 1974479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decrease in the intracellular guanosine 5'-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of Ras, the transforming principle of HL-60 cells.
    Pilz RB; Huvar I; Scheele JS; Van den Berghe G; Boss GR
    Cell Growth Differ; 1997 Jan; 8(1):53-9. PubMed ID: 8993834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin.
    Olah E; Csokay B; Prajda N; Kote-Jarai Z; Yeh YA; Weber G
    Anticancer Res; 1996; 16(5A):2469-77. PubMed ID: 8917337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
    Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
    Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
    Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
    Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
    Sokoloski JA; Sartorelli AC
    Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
    Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
    Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of B16 melanoma cell proliferation and alterations in p21 ras expression induced by interceptors of signal transduction pathways.
    Nordenberg J; Goldwasser I; Zoref-Shani E; Beery E; Sidi Y
    Isr J Med Sci; 1996 Dec; 32(12):1153-7. PubMed ID: 9007143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical issues in chemotherapy with tiazofurin.
    Weber G
    Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation.
    Kharbanda SM; Sherman ML; Spriggs DR; Kufe DW
    Cancer Res; 1988 Nov; 48(21):5965-8. PubMed ID: 2901907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
    Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
    Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.